Last reviewed · How we verify
Ultravate® 0.05% ointment, single exposure
At a glance
| Generic name | Ultravate® 0.05% ointment, single exposure |
|---|---|
| Also known as | Halobetasol |
| Sponsor | Actavis Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects (PHASE1)
- Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultravate® 0.05% ointment, single exposure CI brief — competitive landscape report
- Ultravate® 0.05% ointment, single exposure updates RSS · CI watch RSS
- Actavis Inc. portfolio CI